Key Takeaways

  • Science Corporation secured European marketing approval in July for PRIMA, its subretinal microchip, scheduling its first commercial sales for the coming weeks.
  • Earlier visual prosthetics only generated vague flashes of light, but PRIMA restores coherent form vision to patients who lost their light-sensitive photoreceptor cells.
  • In clinical trials, blind patients with advanced macular degeneration regained enough visual acuity to read books, fill in crosswords, and solve Sudoku puzzles.
  • The system pairs glasses equipped with a laser projector directly to an implant under the retina, bypassing dead rods and cones to send signals straight to the brain.
  • Science Corporation accelerated its timeline by acquiring Pixium's technology and treating neural restoration as an engineering problem rather than a traditional drug discovery loop.

Restoring Sight Through Direct Neural Hardware

For decades, retinal implants produced little more than indistinct flashes of light. Patients could tell if a room had an open window, but they could not read text or recognize everyday objects. Max Hodak, co-founder and CEO of Science Corporation, wanted to bridge that gap by restoring actual form vision.

The breakthrough arrived with PRIMA, a miniature chip placed beneath the retina. Hodak explains the mechanism clearly: “It's a tiny chip that's implanted under the retina in the back of the eye for patients that have gone blind due to loss of the light-sensitive cells in the eye.”

The hardware bypasses damaged rods and cones by pairing the subretinal chip with external glasses. Hodak notes, “The patient wears glasses that have a laser projector that projects an image onto the implant that then stimulates the retina directly to get a visual signal back into the brain.”

The results from human testing crossed an unprecedented threshold. “Nobody had previously ever been able to restore a form vision image in the mind's eye of a blind patient in this way,” Hodak states. Patients who had lost functional vision to conditions like dry age-related macular degeneration regained the ability to process sharp patterns. In the trial, Hodak observed patients performing tasks once thought impossible with neural implants: “The main thing was just the existence proof of like that success was an impossible outcome, right? Like that we had patients filling in Sudoku puzzles or crossword puzzles. There were patients that were reading books.”

Treating Biology as an Engineering Stack

The success of PRIMA points to a broader shift in how hardware builders approach human biology. Traditional biotechnology often searches for chemical compounds to slow down degenerative diseases. That process takes decades and rarely fixes circuits that have already died. Science Corporation took the opposite route: treating the visual pathway as an optical and electrical data pipeline.

When biological photoreceptors stop converting photons into electrical spikes, you do not need to regrow the cells if you can replace their function with microelectronics. By acquiring Pixium's foundational technology and applying fast engineering cycles, Science Corporation pushed the device all the way through European regulatory scrutiny.

“We just in July got marketing approval in Europe for Prima to start commercially selling it there,” Hodak said. “And so, that's a major milestone. That means it's really commercially available. The first sales will happen in the coming weeks.”

The engineering roadmap focuses on resolution and signal quality. Early versions deliver high-contrast form vision, but the development team is already working on adding grayscale depth and color. When you view biological failure modes through a computational lens, medical progress stops waiting on biological luck and starts tracking standard hardware curves.

What to Do With This

Audit the hardest technical bottleneck in your product roadmap this week. If you have spent months waiting for an external discovery or a fragile biological process to cooperate, ask how you can bypass the broken layer entirely with off-the-shelf electronics or deterministic software. Map the input and output of the broken subsystem, specify the signal conversion needed, and prototype a hardware bypass instead of trying to patch the native biological failure.